TY - JOUR
T1 - Correlation of β2-microglobulin with postoperative delirium and 3-year mortality undergoing knee or hip replacement surgery
T2 - a prospective cohort study
AU - Wang, Yuanlong
AU - He, Qian
AU - Fu, Kun
AU - Bi, Yanlin
AU - Wang, Bin
AU - Kong, Wenjie
AU - Hua, Shuhui
AU - Kong, Jian
AU - Xu, Shanling
AU - Gong, Hongyan
AU - Wang, Jiahan
AU - Li, Chuan
AU - Lin, Yanan
AU - Lin, Xu
N1 - Publisher Copyright:
Copyright © 2025 Wang, He, Fu, Bi, Wang, Kong, Hua, Kong, Xu, Gong, Wang, Li, Lin and Lin.
PY - 2025
Y1 - 2025
N2 - Introduction: Postoperative delirium (POD) is a commonly occurring condition in the postoperative period. Therefore, the study intends to investigate the relationship between B2M and POD and the effect of B2M levels on three-year postoperative mortality in patients with POD. Methods: Postoperatively, the Confusion Assessment Method (CAM) and the Monumental Delirium Assessment Scale (MDAS) were used to assess the incidence and severity of POD. Preoperative plasma B2M levels were measured utilizing a latex-enhanced immunoturbidimetric assay. Total tau protein (T-tau), phosphorylated tau protein (P-tau), and amyloid β plaque 42 (Aβ42) were detected in preoperative cerebrospinal fluid (CSF) by enzyme-linked immunosorbent assay. Logistic regression equations were applied to examine the risk factors linked to POD. Patients presenting with POD were grouped according to B2M level and followed up for 3 years postoperatively for their survival and Kaplan–Meier survival curves were plotted. Results: The prevalence of POD was 7.23%. Serum B2M levels were higher in POD patients compared to non-POD (NPOD) patients (p = 0.01). The results of the logistic regression analysis indicated that B2M (OR = 1.394, 95% CI = 1.017–1.910, p = 0.002) and T-tau (OR = 1.006, 95% CI = 1.002–1.011, p = 0.007) posed a risk for POD. B2M and POD were partially associated through the mediation of CSF T-tau (10.0%). The K-M survival curves showed that patients with high B2M who developed POD had a higher mortality rate 3 years after surgery (p = 0.031). Conclusion: In summary, B2M may be a risk factor for POD, which might be mediated in part by CSF T-tau.
AB - Introduction: Postoperative delirium (POD) is a commonly occurring condition in the postoperative period. Therefore, the study intends to investigate the relationship between B2M and POD and the effect of B2M levels on three-year postoperative mortality in patients with POD. Methods: Postoperatively, the Confusion Assessment Method (CAM) and the Monumental Delirium Assessment Scale (MDAS) were used to assess the incidence and severity of POD. Preoperative plasma B2M levels were measured utilizing a latex-enhanced immunoturbidimetric assay. Total tau protein (T-tau), phosphorylated tau protein (P-tau), and amyloid β plaque 42 (Aβ42) were detected in preoperative cerebrospinal fluid (CSF) by enzyme-linked immunosorbent assay. Logistic regression equations were applied to examine the risk factors linked to POD. Patients presenting with POD were grouped according to B2M level and followed up for 3 years postoperatively for their survival and Kaplan–Meier survival curves were plotted. Results: The prevalence of POD was 7.23%. Serum B2M levels were higher in POD patients compared to non-POD (NPOD) patients (p = 0.01). The results of the logistic regression analysis indicated that B2M (OR = 1.394, 95% CI = 1.017–1.910, p = 0.002) and T-tau (OR = 1.006, 95% CI = 1.002–1.011, p = 0.007) posed a risk for POD. B2M and POD were partially associated through the mediation of CSF T-tau (10.0%). The K-M survival curves showed that patients with high B2M who developed POD had a higher mortality rate 3 years after surgery (p = 0.031). Conclusion: In summary, B2M may be a risk factor for POD, which might be mediated in part by CSF T-tau.
KW - mediation analysis
KW - mortality rate
KW - postoperative delirium
KW - prediction model
KW - β2-microglobulin
UR - https://www.scopus.com/pages/publications/105013551171
U2 - 10.3389/fmed.2025.1597764
DO - 10.3389/fmed.2025.1597764
M3 - 文章
AN - SCOPUS:105013551171
SN - 2296-858X
VL - 12
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 1597764
ER -